Vault-13

Ghost Tree Capital, LLC

NEW YORK, NY · CIK 1595851 · 13F filing filed 2024-11-14

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

$275.8m reported value -4.0% vs Q2 2024
50positions
40.4%in top 10
9 new 16 added 22 reduced 18 sold out vs Q2 2024

Options: 2 call positions ($21.1m notional), 2 put positions ($34.2m notional) – listed below, not included above.

Holdings, Q3 2024

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 SAREPTA THERAPEUTICS INC COM SRPT SRPT 120,000 $15.0m5.43% 5.43% AddedShares held: Q4 2023 100.0k, Q1 2024 125.0k, Q2 2024 55.0k, Q3 2024 120.0k +65.0k +65,000 118.2%
2 NOVO-NORDISK A S ADR NVO NVO 110,000 $13.1m4.75% 4.75% NewShares held: Q4 2023 0, Q1 2024 0, Q2 2024 0, Q3 2024 110.0k
3 BLUEPRINT MEDICINES CORP COM BPMC BPMC 140,000 $12.9m4.70% 4.70% AddedShares held: Q4 2023 0, Q1 2024 72.8k, Q2 2024 40.0k, Q3 2024 140.0k +100.0k +100,000 250.0%
4 AXSOME THERAPEUTICS INC COM AXSM AXSM 135,000 $12.1m4.40% 4.40% ReducedShares held: Q4 2023 165.0k, Q1 2024 210.0k, Q2 2024 150.0k, Q3 2024 135.0k -15.0k -15,000 -10.0%
5 TARSUS PHARMACEUTICALS INC COM TARS TARS 350,000 $11.5m4.17% 4.17% AddedShares held: Q4 2023 300.0k, Q1 2024 300.0k, Q2 2024 235.0k, Q3 2024 350.0k +115.0k +115,000 48.9%
6 PERSPECTIVE THERAPEUTICS INC COM NEW CATX CATX 750,000 $10.0m3.63% 3.63% ReducedShares held: Q4 2023 0, Q1 2024 0, Q2 2024 925.0k, Q3 2024 750.0k -175.0k -175,000 -18.9%
7 CG ONCOLOGY INC COM CGON CGON 250,000 $9.4m3.42% 3.42% ReducedShares held: Q4 2023 0, Q1 2024 75.0k, Q2 2024 260.0k, Q3 2024 250.0k -10.0k -10,000 -3.9%
8 ROIVANT SCIENCES LTD SHS ROIV ROIV 800,000 $9.2m3.35% 3.35% ReducedShares held: Q4 2023 600.0k, Q1 2024 1.3m, Q2 2024 1.0m, Q3 2024 800.0k -200.0k -200,000 -20.0%
9 VAXCYTE INC COM PCVX PCVX 80,000 $9.1m3.31% 3.31% ReducedShares held: Q4 2023 70.0k, Q1 2024 95.0k, Q2 2024 150.0k, Q3 2024 80.0k -70.0k -70,000 -46.7%
10 VIKING THERAPEUTICS INC COM VKTX VKTX 140,000 $8.9m3.21% 3.21% AddedShares held: Q4 2023 0, Q1 2024 73.0k, Q2 2024 95.0k, Q3 2024 140.0k +45.0k +45,000 47.4%
11 SYNDAX PHARMACEUTICALS INC COM SNDX SNDX 450,000 $8.7m3.14% 3.14% AddedShares held: Q4 2023 0, Q1 2024 150.0k, Q2 2024 350.0k, Q3 2024 450.0k +100.0k +100,000 28.6%
12 JANUX THERAPEUTICS INC COM JANX JANX 190,000 $8.6m3.13% 3.13% AddedShares held: Q4 2023 0, Q1 2024 0, Q2 2024 50.0k, Q3 2024 190.0k +140.0k +140,000 280.0%
13 ASCENDIS PHARMA A/S SPONSORED ADR SPONSORED ADR 52,500 $7.8m2.84% 2.84% ReducedShares held: Q4 2023 20.0k, Q1 2024 0, Q2 2024 86.7k, Q3 2024 52.5k -34.2k -34,221 -39.5%
14 CRINETICS PHARMACEUTICALS IN COM CRNX CRNX 150,000 $7.7m2.78% 2.78% ReducedShares held: Q4 2023 65.0k, Q1 2024 200.0k, Q2 2024 240.0k, Q3 2024 150.0k -90.0k -90,000 -37.5%
15 SOLENO THERAPEUTICS INC COM SLNO SLNO 150,000 $7.6m2.75% 2.75% ReducedShares held: Q4 2023 112.4k, Q1 2024 200.0k, Q2 2024 300.0k, Q3 2024 150.0k -150.0k -150,000 -50.0%
16 TG THERAPEUTICS INC COM TGTX TGTX 310,000 $7.3m2.63% 2.63% ReducedShares held: Q4 2023 250.0k, Q1 2024 825.0k, Q2 2024 500.0k, Q3 2024 310.0k -190.0k -190,000 -38.0%
17 REZOLUTE INC COM NEW RZLT RZLT 1,474,995 $7.2m2.59% 2.59% AddedShares held: Q4 2023 0, Q1 2024 0, Q2 2024 1.4m, Q3 2024 1.5m +53.5k +53,494 3.8%
18 PHATHOM PHARMACEUTICALS INC COM PHAT PHAT 375,000 $6.8m2.46% 2.46% ReducedShares held: Q4 2023 385.2k, Q1 2024 485.0k, Q2 2024 600.0k, Q3 2024 375.0k -225.0k -225,000 -37.5%
19 MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD MLTX MLTX 128,411 $6.5m2.35% 2.35% ReducedShares held: Q4 2023 80.0k, Q1 2024 300.0k, Q2 2024 300.0k, Q3 2024 128.4k -171.6k -171,589 -57.2%
20 OLEMA PHARMACEUTICALS INC COM OLMA OLMA 535,000 $6.4m2.32% 2.32% ReducedShares held: Q4 2023 0, Q1 2024 200.0k, Q2 2024 550.0k, Q3 2024 535.0k -15.0k -15,000 -2.7%
21 IMMUNOVANT INC COM IMVT IMVT 215,000 $6.1m2.22% 2.22% ReducedShares held: Q4 2023 0, Q1 2024 125.0k, Q2 2024 260.0k, Q3 2024 215.0k -45.0k -45,000 -17.3%
22 INSMED INC COM PAR $.01 INSM INSM 75,000 $5.5m1.99% 1.99% AddedShares held: Q4 2023 0, Q1 2024 150.0k, Q2 2024 65.0k, Q3 2024 75.0k +10.0k +10,000 15.4%
23 EDGEWISE THERAPEUTICS INC COM EWTX EWTX 195,000 $5.2m1.89% 1.89% NewShares held: Q4 2023 0, Q1 2024 0, Q2 2024 0, Q3 2024 195.0k
24 REPLIMUNE GROUP INC COM REPL REPL 450,000 $4.9m1.79% 1.79% UnchangedShares held: Q4 2023 400.0k, Q1 2024 650.0k, Q2 2024 450.0k, Q3 2024 450.0k
25 BRIDGEBIO PHARMA INC COM BBIO BBIO 175,000 $4.5m1.62% 1.62% AddedShares held: Q4 2023 125.0k, Q1 2024 175.0k, Q2 2024 140.0k, Q3 2024 175.0k +35.0k +35,000 25.0%
26 TAYSHA GENE THERAPIES INC COM SHS TSHA TSHA 2,150,000 $4.3m1.57% 1.57% AddedShares held: Q4 2023 2.1m, Q1 2024 950.0k, Q2 2024 1.2m, Q3 2024 2.1m +900.0k +900,000 72.0%
27 RHYTHM PHARMACEUTICALS INC COM RYTM RYTM 78,842 $4.1m1.50% 1.50% ReducedShares held: Q4 2023 0, Q1 2024 125.0k, Q2 2024 117.4k, Q3 2024 78.8k -38.5k -38,546 -32.8%
28 ANNEXON INC COM ANNX ANNX 650,000 $3.8m1.40% 1.40% AddedShares held: Q4 2023 0, Q1 2024 0, Q2 2024 310.0k, Q3 2024 650.0k +340.0k +340,000 109.7%
29 KORRO BIO INC COM KRRO KRRO 110,000 $3.7m1.33% 1.33% AddedShares held: Q4 2023 0, Q1 2024 0, Q2 2024 100.0k, Q3 2024 110.0k +10.0k +10,000 10.0%
30 DYNE THERAPEUTICS INC COM DYN DYN 100,000 $3.6m1.30% 1.30% NewShares held: Q4 2023 0, Q1 2024 0, Q2 2024 0, Q3 2024 100.0k
31 ARVINAS INC COM ARVN ARVN 145,000 $3.6m1.29% 1.29% AddedShares held: Q4 2023 59.2k, Q1 2024 40.0k, Q2 2024 75.0k, Q3 2024 145.0k +70.0k +70,000 93.3%
32 CORBUS PHARMACEUTICALS HLDGS COM NEW CRBP CRBP 160,000 $3.3m1.20% 1.20% ReducedShares held: Q4 2023 0, Q1 2024 56.9k, Q2 2024 175.0k, Q3 2024 160.0k -15.0k -15,000 -8.6%
33 HELIX ACQUISITION CORP II CL A ORD SHS BBOT BBOT 300,000 $3.1m1.14% 1.14% UnchangedShares held: Q4 2023 0, Q1 2024 300.0k, Q2 2024 300.0k, Q3 2024 300.0k
34 NUVATION BIO INC COM CL A NUVB NUVB 1,350,000 $3.1m1.12% 1.12% AddedShares held: Q4 2023 0, Q1 2024 0, Q2 2024 1.1m, Q3 2024 1.4m +200.0k +200,000 17.4%
35 SAVARA INC COM SVRA SVRA 725,000 $3.1m1.11% 1.11% ReducedShares held: Q4 2023 750.0k, Q1 2024 1.6m, Q2 2024 1.1m, Q3 2024 725.0k -325.9k -325,876 -31.0%
36 TENAYA THERAPEUTICS INC COM TNYA TNYA 1,500,000 $2.9m1.05% 1.05% AddedShares held: Q4 2023 0, Q1 2024 775.0k, Q2 2024 1.4m, Q3 2024 1.5m +150.0k +150,000 11.1%
37 REGENXBIO INC COM RGNX RGNX 265,000 $2.8m1.01% 1.01% AddedShares held: Q4 2023 0, Q1 2024 120.0k, Q2 2024 170.0k, Q3 2024 265.0k +95.0k +95,000 55.9%
38 CORVUS PHARMACEUTICALS INC COM CRVS CRVS 500,000 $2.6m0.96% 0.96% NewShares held: Q4 2023 0, Q1 2024 0, Q2 2024 0, Q3 2024 500.0k
39 ABSCI CORPORATION COM ABSI ABSI 550,000 $2.1m0.76% 0.76% NewShares held: Q4 2023 0, Q1 2024 0, Q2 2024 0, Q3 2024 550.0k
40 NEUROGENE INC COM NGNE NGNE 50,000 $2.1m0.76% 0.76% ReducedShares held: Q4 2023 0, Q1 2024 25.0k, Q2 2024 70.0k, Q3 2024 50.0k -20.0k -20,000 -28.6%
41 CAPRICOR THERAPEUTICS INC COM NEW CAPR CAPR 125,000 $1.9m0.69% 0.69% NewShares held: Q4 2023 0, Q1 2024 0, Q2 2024 0, Q3 2024 125.0k
42 APELLIS PHARMACEUTICALS INC COM APLS APLS 65,000 $1.9m0.68% 0.68% ReducedShares held: Q4 2023 0, Q1 2024 130.0k, Q2 2024 135.0k, Q3 2024 65.0k -70.0k -70,000 -51.9%
43 SUMMIT THERAPEUTICS INC COM SMMT SMMT 85,000 $1.9m0.67% 0.67% NewShares held: Q4 2023 0, Q1 2024 0, Q2 2024 0, Q3 2024 85.0k
44 SPYRE THERAPEUTICS INC COM NEW SYRE SYRE 60,000 $1.8m0.64% 0.64% ReducedShares held: Q4 2023 0, Q1 2024 100.0k, Q2 2024 250.2k, Q3 2024 60.0k -190.2k -190,237 -76.0%
45 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 75,000 $1.7m0.62% 0.62% ReducedShares held: Q4 2023 300.0k, Q1 2024 625.0k, Q2 2024 587.7k, Q3 2024 75.0k -512.7k -512,708 -87.2%
46 PROQR THRAPEUTICS N V SHS EURO PRQR PRQR 887,700 $1.6m0.59% 0.59% ReducedShares held: Q4 2023 0, Q1 2024 0, Q2 2024 900.0k, Q3 2024 887.7k -12.3k -12,300 -1.4%
47 ATYR PHARMA INC COM NEW ATYR ATYR 800,000 $1.4m0.51% 0.51% UnchangedShares held: Q4 2023 0, Q1 2024 600.0k, Q2 2024 800.0k, Q3 2024 800.0k
48 LARIMAR THERAPEUTICS INC COM LRMR LRMR 200,000 $1.3m0.48% 0.48% NewShares held: Q4 2023 0, Q1 2024 210.6k, Q2 2024 0, Q3 2024 200.0k
49 ENGENE HOLDINGS INC COM COM 160,898 $1.1m0.39% 0.39% ReducedShares held: Q4 2023 0, Q1 2024 200.0k, Q2 2024 420.3k, Q3 2024 160.9k -259.4k -259,433 -61.7%
50 AMYLYX PHARMACEUTICALS INC COM AMLX AMLX 325,000 $1.1m0.38% 0.38% NewShares held: Q4 2023 0, Q1 2024 0, Q2 2024 0, Q3 2024 325.0k

Sold out since Q2 2024

SecurityTickerShares held beforeValue then
BIOHAVEN LTD BHVN BHVN 490,000 $17.0m490.0k shares
ALNYLAM PHARMACEUTICALS INC ALNY ALNY 22,500 $5.5m22.5k shares
ACADIA PHARMACEUTICALS INC ACAD ACAD 225,000 $3.7m225.0k shares
CABALETTA BIO INC CABA CABA 370,899 $2.8m370.9k shares
CYTOKINETICS INC CYTK CYTK 33,200 $1.8m33.2k shares
ELEVATION ONCOLOGY INC 600,000 $1.6m600.0k shares
KRYSTAL BIOTECH INC KRYS KRYS 8,500 $1.6m8.5k shares
WAVE LIFE SCIENCES LTD 96663EUR 96663EUR 200,000 $998.0k200.0k shares
ARROWHEAD PHARMACEUTICALS IN ARWR ARWR 35,000 $909.6k35.0k shares
SAGIMET BIOSCIENCES INC SGMT SGMT 225,000 $769.5k225.0k shares
INTRA-CELLULAR THERAPIES INC ITCI ITCI 10,000 $684.9k10.0k shares
MACROGENICS INC MGNX MGNX 150,000 $637.5k150.0k shares
PMV PHARMACEUTICALS INC PMVP PMVP 375,000 $607.5k375.0k shares
PTC THERAPEUTICS INC PTCT PTCT 19,000 $581.0k19.0k shares
REVANCE THERAPEUTICS INC RVNC RVNC 225,000 $578.2k225.0k shares
INTELLIA THERAPEUTICS INC NTLA NTLA 25,000 $559.5k25.0k shares
AN2 THERAPEUTICS INC ANTX ANTX 219,331 $471.6k219.3k shares
CYTOMX THERAPEUTICS INC CTMX CTMX 300,000 $366.0k300.0k shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
SPDR SER TR XBI · Put XBIPut 300,000 $29.6m300.0k shares New
BIOHAVEN LTD BHVN · Call BHVNCall 348,778 $17.4m348.8k shares New
CORBUS PHARMACEUTICALS HLDGS CRBP · Put CRBPPut 220,000 $4.5m220.0k shares New
INSMED INC INSM · Call INSMCall 50,000 $3.6m50.0k shares Reduced